(Total Views: 269)
Posted On: 03/06/2019 10:12:03 AM
Post# of 72446
there is no efficiency .. that is the CON (among many) perpetrated by the powers that be
just like a stock that triggers reg sho is supposed to have a buy in
but what usually happens is when NR (non retail) is so upside down
that the only recourse a *targeted* company/stock winds up doing
is a secondary *offering*
it's an offering alright .. on the altar of extortion
it's beyond repugnant what is expected .. let alone tolerated
it's a slick system that few understand .. but once one is educated to it
the game can be played back somewhat against NR by retail (by knowing
what they are invested in and not being shaken out by the oldest trick in NRs' playbook)
and to an extent (sequence and timing of material events) by an aware mgmt re: execution
4kids
Another example of a biotech once left for dead and now successful. You don't need to read this article or care about their drug (not relevant to IPIX) to understand the chart.
Article
https://endpts.com/focused-on-its-2nd-commerc...givosiran/
Chart
http://bigcharts.marketwatch.com/quickchart/q...mp;time=20
By the way, they have a 9.3 Billion market cap, are not profitable, are projected to lose money again this year (lots of money), and just had a mixed-result clinical trial -- results were good but bad side effects.
They have one approved drug, which their 2nd drug might replace. It is for a rare disease.
So, a 9.3 Billion market cap for a company that is unlikely to affect as many patients as Brilacidin-OM would reach.
IPIX market cap is just under 26 Million.
Efficient markets, what a laugh.
Read More: https://investorshangout.com/post/newpost/873...z5hP9jhKiw
just like a stock that triggers reg sho is supposed to have a buy in
but what usually happens is when NR (non retail) is so upside down
that the only recourse a *targeted* company/stock winds up doing
is a secondary *offering*
it's an offering alright .. on the altar of extortion
it's beyond repugnant what is expected .. let alone tolerated
it's a slick system that few understand .. but once one is educated to it
the game can be played back somewhat against NR by retail (by knowing
what they are invested in and not being shaken out by the oldest trick in NRs' playbook)
and to an extent (sequence and timing of material events) by an aware mgmt re: execution
4kids
Another example of a biotech once left for dead and now successful. You don't need to read this article or care about their drug (not relevant to IPIX) to understand the chart.
Article
https://endpts.com/focused-on-its-2nd-commerc...givosiran/
Chart
http://bigcharts.marketwatch.com/quickchart/q...mp;time=20
By the way, they have a 9.3 Billion market cap, are not profitable, are projected to lose money again this year (lots of money), and just had a mixed-result clinical trial -- results were good but bad side effects.
They have one approved drug, which their 2nd drug might replace. It is for a rare disease.
So, a 9.3 Billion market cap for a company that is unlikely to affect as many patients as Brilacidin-OM would reach.
IPIX market cap is just under 26 Million.
Efficient markets, what a laugh.
Read More: https://investorshangout.com/post/newpost/873...z5hP9jhKiw
(2)
(0)
